NEW YORK (GenomeWeb News) — Ciphergen Biosystems’ shareholders have given the company the green light to sell its proteomics instrument business to Bio-Rad Laboratories.
Under the terms of the agreement, originally disclosed in August, Ciphergen will unload the hardware branch to Bio-Rad for about $20 million in cash and a $3 million equity investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.